21 CFR Part 11 starts with the required record

Scope begins outside the software feature list

Section 11.1 ties the rule to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under FDA record requirements, and to specified electronic submissions. That makes the underlying record obligation and intended use the starting point. A team first needs to identify the record, the governing requirement, the official copy, the people and systems that act on it, and any stated exclusion.

This boundary matters when one platform holds regulated records, reference material, drafts, analytics, and ordinary business content together. Treating every object as identical can waste control effort; treating the product name as proof of scope can omit important records. A defensible inventory preserves the record type and regulatory context alongside system, workflow, owner, retention, and signature use.

Controls protect a record through its use

For closed systems, section 11.10 describes procedures and controls designed to protect authenticity, integrity, and, when appropriate, confidentiality. Its listed controls include system validation, accurate and complete copies in human-readable and electronic form, ready retrieval throughout retention, authorized access, secure time-stamped audit trails, operational checks, authority checks, qualified personnel, accountability policies, and controlled system documentation.

Those elements are connected. An audit trail is not persuasive if identity, authority, time, source data, or record retention is unreliable. A human-readable copy does not establish that the electronic record is complete. A configured permission does not establish that the authorized role remains correct. Evaluation should therefore follow an actual record through creation, review, change, signature, retrieval, inspection copy, and archival rather than count isolated features.

Signatures need meaning and record linkage

Part 11 requires signed electronic records to show the printed name of the signer, the execution date and time, and the meaning associated with the signature, such as review, approval, responsibility, or authorship. It also requires electronic and handwritten signatures executed to electronic records to remain linked to their respective records so they cannot be removed or transferred by ordinary means to falsify another record.

A useful demonstration should show more than a signature image or approval button. Buyers can inspect identity proofing, unique account administration, signature meaning, record version, time source, displayed and exported manifestations, linkage after migration, failed and revoked access, and the evidence retained when a signed record is corrected. The regulation sets requirements; it does not establish that any observed implementation meets them.

Validation remains use-specific

Section 11.10 calls for validation of systems to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records. The operative phrase is intended performance. A vendor can provide design information, test evidence, security material, release notes, and configurable controls, but the regulated organization still has to define its intended use and govern the implemented process.

Buyers should separate product evidence from configured-process evidence. Ask what the vendor tests, what the customer must configure and verify, how releases are assessed, how records and audit trails migrate, how exceptions are handled, and what is unavailable for inspection. This source alone does not determine validation depth, acceptability of a particular control, or compliance for a specific system.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.